![]() Therapeutic inertia in the management of hyperglycaemia in patients with type 2 diabetes is a major concern. Diversity of inertia measures precluded meta-analysis. Data were mainly available from Western countries. Therapeutic inertia increased as the number of antidiabetic drugs rose and decreased with increasing HbA1c levels. In most studies, the median time to treatment intensification after a glycated haemoglobin (HbA1c) measurement above target was more than 1 year (range 0.3 to >7.2 years). Data from low- to middle-income countries were scarce. ![]() Measurements used to assess therapeutic inertia varied across studies, making comparisons difficult. The final selection for the review included 53 articles. ![]() Data were extracted by a single researcher using a standardized data extraction form. Two researchers independently screened all of the titles and abstracts, and the full texts of publications deemed relevant. Systematic searches for articles published from Januto Augwere conducted in MEDLINE and Embase. The aims of this systematic review were to identify how therapeutic inertia in the management of hyperglycaemia was measured and to assess its extent over the past decade. ![]() Therapeutic inertia, defined as the failure to initiate or intensify therapy in a timely manner according to evidence-based clinical guidelines, is a key reason for uncontrolled hyperglycaemia in patients with type 2 diabetes. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |